Martínez PY, Abdel YA, Abreu GMR

Idioma: Español
Referencias bibliográficas: 28
Paginas: 69-82
Archivo PDF: 135.59 Kb.

RESUMEN

En la historia natural de la cirrosis hepática, aproximadamente 50 % de los pacientes presentan su primera descompensación en forma de ascitis, esta a su vez, si no es tratada adecuadamente, puede originar complicaciones mucho más severas como la peritonitis bacteriana espontánea y otras, quizás irreversibles, como el síndrome hepatorrenal. Alrededor de 60 % de los pacientes con cirrosis compensada desarrollan ascitis en los primeros 10 años después del diagnóstico. Se revisó este tema con el objetivo de disminuir el número de complicaciones y fallecidos por esta causa.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Runyou BA. AASLD Practice guidelines committee. Management of adult patients with ascites due to cirrhosis: an up date. Hepatology. 2009;49(6):2087-107.

2. Salermo F, Camma C, Enea M, Rossie M, Wong F. Transyugular intrahepatic portosystemic shunt for refractory ascites: a meta analysis of individual patient data. Gastroenterology. 2007;133:825-34.

3. Singh V, Dheerendra PC, Singh B. Midridines versus albumin in the prevention of paracentesis-induce circulatory dysfunction in the cirrotics: a randomized pilot study. Am J Gastroenterology. 2008;103:1399-405.

4. Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure. Part I: Diagnosis and evaluation. Am Fam Physician. 2006;74:756-62.

5. Gines P, Wong F, Watson M, Ruiz-Del-Arbol L, Bilic A, Dobru D. Effects of satavanptan, a selective vasopressin V2 receptor antagonist, on ascites and serum in cirrhosis with hiponatremia. Hepatology. 2008;48:204-13.

6. Gines P, Wong H, Terg R, Brua R, Zarski P. Clinical trial: short term effects of combination of satavaptan, a selective vasopressin V receptor antagonist, and diurects on ascites in patients witch cirrhosis without hypernatremia- a randomized double blind placebo controlled study. Aliment Pharmacol Ther. 2010;31:834-45.

7. Wong F, Gines P, Watson H, Horsmans Y, Angeli P, Gow P, et al. Effect of a selective vasopressin V2 recpetor antagonist, satavaptan, on ascites recurrence after paracentesis in patients in patients with cirrhosis. J Hepatol. 2010;53:283-90.

8. Wong F, Bernardi M, Horsmans Y, Cabrijan z, Watson H, Gies P. Effects of satavaptan, an oral vasopressin v2 receptor antagonist, on management of ascites and mosbidity in liver cirrhosis i a long-terms, placebo-controlled study. J Hepatol. 2009;50:542-3.

9. Heidelbaugh JJ, Sherbondy M. Cirrhosis and chronic liver failure. Part II: Complications and treatment. Am Fam Physician. 2006;776579.

10. Fosolato S, Angeli P, Dallagnese l, Maresio G Zola E, Mazza E, et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical feature. Hepatology. 2007;45:223-9.

11. Heidelbaugh Joel J, Sherbondy M. University of Michigan Medical School, Ann Arbor, Michigan. Cirrhosis and Chronic Liver Failure: Part II. Complications and Treatment. Am Fam Physician. 2006 Sep 1;74(5):767-76.

12. Salerno F, Gerbes A, Gine SP. Wong F, Vicente A. American Association for the Study of Liver Disease. Diagnóstico, prevención y tratamiento del síndrome hepatorrenal en la cirrosis. Gut. 2007;65:1310-8.

13. Terg R, Gadano A, Cartier M, Casciato P, Lucero R, Muñoz A, et al. Serum creatinine and bilirrubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study. Liver Int. 2009;29:415-9.

14. Terg R, Fassio E, Guevara M, Cartier M, Longo C, Lucero R, et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebocontrolled study. J Hepatol. 2008;48:774-9.

15. Hyponatremia treatment guidelines 2007. Expert panel recommendations. Am J Med. 2007;120:51-2.

16. Dawas MF, Lewsey JD, Neuberger J. The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study. Liver Transpl. 2007;13:1115-1124.

17. Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49:208710.

18. Appenrodt B, Wolf A, Grunhage F. Prevention of paracentesis induced circulatory dysfunction: midodrine versus albumin. A randomized pilot study. Liver Int. 2008;28:101925.

19. De Gottardi A, Thevenot T, Spahr L. Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study. Clin Gastroenterol Hepatol. 2009;7:9069.

20. Salerno F, Merli M, Riggio O. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology. 2004;40:62935.

21. D'Amico G, Luca A, Morabito A. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology. 2005;129:1282-93.

22. Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension: update 2009. Hepatology. 2010;51:306.

23. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int. 2006;69 2124-30.

24. Decaux G, Soupart A, Vassart G. Non-peptide argininevasopressin antagonists: the vaptans. Lancet. 2008;371:1624-32.

25. Castellote J, Girbau A, Maisterra S. Spontaneous bacterial peritonitis and bacterascites prevalencein symptomatic cirrhotic outpatients undergoing large volume paracentesis. J Gastroenterol Hepatol. 2008;23:2569.

26. Garcia-Tsao G. Bacterial infections in cirrhosis: treatment and prophylaxis. J Hepatol. 2005;42:S8592.

27. Fernández J, Navasa M, Planas R. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007;133:818-24.

28. Gerbes AL, Gulberg V. Benefit of TIPS for patients with refractory or recidivant ascites: serum bilirubin may make the difference. Hepatology. 2005;41:217.